Product Description
BMS-986470 is a dual ZBTB7A/WIZ molecular glue degrader. It's chemical structure was disclosed during the First Disclosures session at the ACS Fall 2025 meeting. BMS-986470 reactivates functional fetal hemoglobin (HbF) expression in adult hematopoietic cells, and it is proposed as a disease-modifying agent for sickle cell disease, and other hemoglobinopathies. (Sourced from: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=14200)
Mechanisms of Action: CRBN Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Bristol-Myers Squibb
Company Location: Eastern America
Company Founding Year: 1989
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, France, Italy, United Kingdom, United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Anemia, Sickle Cell
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06481306 |
CA230-1019 | P2 |
Recruiting |
Anemia, Sickle Cell |
2028-04-30 |
57% |
2026-07-07 |
|
2023-510283-12-00 |
CA230-1019 | P2 |
Not yet recruiting |
Anemia, Sickle Cell |
2027-11-18 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/19/2024 |
News Article |
Bristol Myers Squibb's Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms |